Literature DB >> 8600463

Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.

Y Ohta1, H Kijima, T Ohkawa, M Kashani-Sabet, K J Scanlon.   

Abstract

In this study, we have compared the efficacy of a tissue-specific promoter (tyrosinase promoter) with a viral promoter to express anti-ras ribozyme RNA in human melanoma cells. The retroviral vector containing the tyrosinase promoter was superior in its ability to suppress the human melanoma phenotype in vitro as characterized by changes in growth, melanin synthesis, morphology and H-ras gene expression. These data support the use of tissue-specific expression of anti-oncogene ribozymes as a rational therapeutic strategy in human cancers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8600463      PMCID: PMC145712          DOI: 10.1093/nar/24.5.938

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  23 in total

Review 1.  Antisense inhibition of oncogene expression.

Authors:  L Neckers; L Whitesell; A Rosolen; D A Geselowitz
Journal:  Crit Rev Oncog       Date:  1992

2.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

Review 3.  Liposomes for the transformation of eukaryotic cells.

Authors:  P Hug; R G Sleight
Journal:  Biochim Biophys Acta       Date:  1991-07-26

Review 4.  Molecular themes in oncogenesis.

Authors:  J M Bishop
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

5.  Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.

Authors:  K J Scanlon; L Jiao; T Funato; W Wang; T Tone; J J Rossi; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 6.  Analysis of mammalian pigmentation at the molecular level.

Authors:  V J Hearing; M Jiménez
Journal:  Pigment Cell Res       Date:  1989 Mar-Apr

7.  Design of RNA enzymes distinguishing a single base mutation in RNA.

Authors:  M Koizumi; Y Hayase; S Iwai; H Kamiya; H Inoue; E Ohtsuka
Journal:  Nucleic Acids Res       Date:  1989-09-12       Impact factor: 16.971

Review 8.  Application of ribozymes to cancer gene therapy.

Authors:  M Kashani-Sabet; K J Scanlon
Journal:  Cancer Gene Ther       Date:  1995-09       Impact factor: 5.987

9.  The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina.

Authors:  M Klüppel; F Beermann; S Ruppert; E Schmid; E Hummler; G Schütz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

10.  A human melanoma cell line established from xenograft in athymic mice.

Authors:  K M Tveit; O Fodstad; J V Johannessen; S Olsnes
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

View more
  8 in total

Review 1.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

Review 2.  Antisense approaches to the gene therapy of cancer--'Recnac'.

Authors:  I Gibson
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

3.  Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.

Authors:  S J Collis; A Tighe; S D Scott; S A Roberts; J H Hendry; G P Margison
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

4.  Ribozyme as an approach for growth suppression of human pancreatic cancer.

Authors:  H Kijima; K J Scanlon
Journal:  Mol Biotechnol       Date:  2000-01       Impact factor: 2.695

Review 5.  Targeted therapy for malignant melanoma.

Authors:  C K Brown; J M Kirkwood
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 6.  Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy.

Authors:  Spencer J Collis; Kevin Khater; Theodore L DeWeese
Journal:  World J Urol       Date:  2003-08-13       Impact factor: 3.661

7.  New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.

Authors:  O A Patutina; N L Mironova; V V Vlassov; M A Zenkova
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

8.  Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line.

Authors:  T Tokunaga; T Tsuchida; H Kijima; K Okamoto; Y Oshika; N Sawa; Y Ohnishi; H Yamazaki; S Miura; Y Ueyama; M Nakamura
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.